COMPANY:

Sophia Genetics

"SOPHiA GENETICS...announced a strategic partnership with Strand Life Sciences...to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and innovative diagnostics solutions."

“SOPHiA GENETICS…announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.”

"SOPHiA GENETICS...announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing. This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing."

"SOPHiA GENETICS...and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those facing renal cell carcinoma (RCC), with the results recently published in npj Precision Oncology. The findings of the study showed the artificial intelligence (AI) model co-constructed by SOPHiA GENETICS and UroCCR provided a strong prediction for post-operative outcomes when compared to usual prognostic scores. This publication follows a prior collaboration that demonstrated the value of multimodal analysis on pre-operative kidney cancer upstaging."

"SOPHiA GENETICS...announced that Universidad de Costa Rica El Centro de Investigación en Cirugía y Cáncer (CICICA) is now live on the SOPHiA DDM™ Platform. The Surgery and Cancer Research Center is using SOPHiA GENETICS to expand its ability to trace, diagnose, and treat rare and inherited diseases among Costa Ricans."

"SOPHiA GENETICS...announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country....With today's announcement, AstraZeneca Spain named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain."

"SOPHiA GENETICS...announced that Medicinski fakultet Univerziteta u Beogradu is live on the SOPHiA DDM™ Platform. The University, which is located in the capital city of Serbia, will use SOPHiA GENETICS’ technology, particularly the hematology-oncology application, to support the enhanced and accurate analysis of lymphoid neoplasms, which are the most common type of blood cancer affecting more than 100,000 people."

"SOPHiA GENETICS...announced that Bioma4me...is now live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETICS’ technology to advance and streamline its genetic testing capabilities...Through the SOPHiA DDM™ Platform, Bioma4me will be able to apply its next generation sequencing (NGS) expertise to the whole exome."

"SOPHiA GENETICS...announced that RareCyte Inc...is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its Precision Biology Services portfolio...The SOPHiA GENETICS technology will help RareCyte's team of scientists and engineers as they continue to develop next-generation products and services that advance precision medicine and biomedical research."

"SOPHiA GENETICS...announced that Karkinos Healthcare...will partner with SOPHiA GENETICS and adopt the SOPHiA DDM™ Platform to advance cancer testing and research for blood cancers and solid tumors to underserved areas in low and middle-income countries."

"SOPHiA GENETICS...announced a collaboration with Exactis Innovation, based in Montreal, Quebec, who will contribute to cancer research and data-driven decision-making through SOPHiA GENETICS’ multimodal real-world data offering...Exactis will join the SOPHiA DDM™ network and leverage the SOPHiA DDM™ platform to access global real-world data insights from multimodal datasets. By joining the SOPHiA DDM™ network, Exactis researchers will access to a global network of data that will provide robust, diverse insights to help support research for its Canadian population."

"SOPHiA GENETICS...announced that OmiCure®...is live on the SOPHiA DDM™ Platform. OmiCure, which works to expand the use of data-driven medicine via its tumor profiling tests, will use SOPHiA GENETICS’ technology to enhance its offerings in support of physicians and patients."

"SOPHiA GENETICS...announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation is an expansion of its existing work with SOPHiA GENETICS."

"SOPHiA GENETICS...announced an expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy. The range of solutions, including MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions, will help progress oncology research and tumor mutation profiling. The rollout of SOPHiA GENETICS' liquid biopsy capabilities demonstrates the company's commitment to developing advanced solutions that empower timely, critical decision-making and improve health outcomes."

"SOPHiA GENETICS...announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France. The hospital system will use the SOPHiA DDM™ Platform to progress its pharmacogenomics research."

"SOPHiA GENETICS...announced the expansion of its relationship with the Città della Salute e della Scienza di Torino located in Turin, Italy. The hospital, which used SOPHiA GENETICS after a public tender in 2021 to optimize workflows and support research in the areas of hereditary cancer, neurological disorders, solid tumors, hematology and rare disease, will further expand its usage of the SOPHiA DDM™ Platform to support research on homologous recombination repair (HRR) biomarkers that indicate treatment options for ovarian, prostate, breast and pancreatic cancers."

"SOPHiA GENETICS...announced that the German company OnkoMedeor Diagnostics MVZ GmbH is now live on the SOPHiA DDM™ Platform. OnkoMedeor Diagnostics MVZ GmbH, which is a haematological lab and part of the Haematological Center Dachau (HAEZ) certified by the German Cancer Society (DKG), handles the diagnosis and treatment of blood and tumor diseases and will use SOPHiA GENETICS’ technology to expand its offerings, advance research and streamline workflow."

"SOPHiA GENETICS...announced that BioReference® Health, LLC...will implement SOPHiA GENETICS’ technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024."

"SOPHiA GENETICS...announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca...to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide....The partnership will provide MSK's proprietary liquid biopsy and solid tumor cancer tests – MSK-ACCESS^® and MSK-IMPACT^® – to organizations via the decentralized, technology-agnostic SOPHiA DDM™ Platform. This offering will be rapidly deployed by SOPHiA GENETICS with support from AstraZeneca's global footprint."

"SOPHiA GENETICS...announced that Shaare Zedek...is now live on the SOPHiA DDM™ Platform. The Platform will enable Shaare Zedek to advance its insights the treatment of myeloid disorders and further develop the application of precision medicine...With the SOPHiA DDM™ Platform, Shaare Zedek Medical Center will retain complete ownership of its database, supporting the research team as it continues to increase its expertise."

"SOPHiA GENETICS...has expanded its relationship with Laboratorio Curie...Laboratorio Curie is now live on the SOPHiA DDM™ Platform and will use the technology to deploy a new test that will identify BRCA gene mutations. Discoveries made using this test aim to enable Laboratorio Curie to support the increased use of precision medicine for hereditary cancers within the country."

"SOPHiA GENETICS...announced that the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', an oncology center in Italy, is using the SOPHiA DDM™ Platform to power a new genomic test that will be used to aid physicians in developing personalized treatment plans for those with advanced ovarian cancer...With use of the SOPHiA DDM™ Platform, the test will help identify patients with a homologous recombination deficiency (HRD), which is caused by a cell's impaired ability to repair DNA double-stranded breaks."

"SOPHiA GENETICS...announced that CHU Bordeaux...has completed implementation of the SOPHiA DDM™ Platform into its organization. The hospital will be using the SOPHiA GENETICS technology to help advance its research on homologous recombination repair (HRR) mutated cancers."

"SOPHiA GENETICS...announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe. With the expanded relationship SOPHiA GENETICS will now further support Gustave Roussy via the SOPHiA DDM™ Platform, which will provide expedited analysis and insights of genomic profiles...Gustave Roussy will now utilize the SOPHiA DDM™ Platform for all relevant samples, including those related to solid tumors, hematologic and hereditary cancers."

"SOPHiA GENETICS...announced that the Tulane University School of Medicine in New Orleans, Louisiana is live on SOPHiA GENETICS technology. The 15th oldest medical school in the United States, Tulane University School of Medicine has a longstanding history of medical research and education and will leverage the SOPHiA DDM™ Platform to help scale its hematologic (blood) testing program to advance blood cancer research."

"SOPHiA GENETICS...announced Gruppo Centro Servizi Medici (CSM)...is live on SOPHiA GENETICS technology. CSM has implemented the SOPHiA DDM™ Platform to help expand its current next-generation sequencing (NGS) offerings and advance its research of hereditary cancer and homologous recombination deficiency (HRD)."

"SOPHiA GENETICS...announced Centre Hospitalier de Bastia is live on the SOPHiA DDM™ Platform. Centre Hospitalier de Bastia, a general hospital located in the city of Bastia, on the French island of Corsica, is using the SOPHiA DDM™ Platform to introduce in-house next-generation sequencing (NGS), which will support their clinical oncology research and facilitate deeper insights into hematologic malignancies."

"SOPHiA GENETICS...announced that Ankara Etlik City Hospital...is live on the SOPHiA DDM™ Platform. The hospital, which opened its doors in September 2022 and serves roughly 15,000 patients daily, will utilize multiple SOPHiA GENETICS solutions to streamline genomic testing, specifically associated with hereditary disorders."

"SOPHiA GENETICS...announced a strategic alliance with NOMAD Genetics...Through the seamless deployment of SOPHiA GENETICS’ trailblazing SOPHiA DDM™ Platform, NOMAD Genetics is augmenting its research capabilities while elevating its operational efficiency...Through the implementation of the SOPHiA GENETICS Platform, NOMAD Genetics will be able to more quickly and accurately identify HRD-positive cancers and utilize a streamlined workflow that will help accelerate rare and inherited disease research."

"SOPHiA GENETICS...announced...at ASCO that it has joined as a founding member of CancerX...As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research. SOPHiA GENETICS offers its SOPHiA DDM™ Platform, powered by artificial intelligence and machine learning, to help advance the inaugural project, which looks to improve equity and reduce cost in cancer treatments."

"SOPHiA GENETICS...announced that the Institute of Oncology Ljubljana (IOL)...based in Ljubljana, Slovenia, is live on SOPHiA DDM™. To help advance its clinical oncology research, IOL is leveraging low-pass Whole Genome Sequencing (WGS) data computed by the proprietary GIInger deep-learning algorithm from SOPHiA GENETICS to increase research efficiency and obtain actionable clinical insights to make data-driven decisions that improve the quality of patient care...IOL will use SOPHiA DDM™ to identify Homologous Recombination Deficiency (HRD) in tumor samples."

"SOPHiA GENETICS...celebrates...with longstanding partner, Dasa...as it reaches a milestone of 2,000 samples analyzed for HRD status. This milestone comes just one year after implementing the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution....Dasa then implemented the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution in March 2022."

"SOPHiA GENETICS...announced that Natural State Laboratories, a xfull-service, state-of-the-art molecular laboratory based in Little Rock, Arkansas, has chosen SOPHiA GENETICS technology to help them expand their cancer testing and research capabilities. Natural State Laboratories will soon begin using SOPHiA DDM™ to launch in-house testing for hereditary cancers. The SOPHiA DDM™ technology will streamline and expedite analysis and interpretation workflows for Natural State Laboratories, increasing the volume of genomic profiles analyzed."

"SOPHiA GENETICS...announced that Unipath Specialty Laboratory Limited...is live on the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Using SOPHiA GENETICS’ technology, Unipath Specialty Laboratory Limited has launched HRD Gene Panel, its latest offering in the field of cancer genomics...The SOPHiA DDM HRD Solution will enable Unipath Specialty Laboratory Limited to retain full ownership of their data, saving time and expense, while offering comprehensive genomic insights powered by deep learning algorithms."

"SOPHiA GENETICS...announced that Krsnaa Diagnostics...is live on SOPHiA DDM™ technology. Krsnaa Diagnostics is using the SOPHiA DDM™ for Hereditary Cancers Solution to expand their current next-generation sequencing (NGS) offerings...With SOPHiA GENETICS technology Krsnaa will advance its NGS offerings and help to democratize data-driven medicine."

"SOPHiA GENETICS...announced that Tel Aviv Sourasky Medical Center (Ichilov)...has chosen to use SOPHiA DDM™ to enhance its genetic testing capabilities. The facility, which serves a population of one million people, will use the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution to help advance its clinical oncology research."

"SOPHiA GENETICS...announced that Acutis Diagnostics...will use SOPHiA DDM™ to develop a new genomic assay. This new next-generation sequencing (NGS) test will build on Acutis Diagnostics’ track record of approved lab-developed tests that support clinical trials, cancer research and treatment...To create the new assay, Acutis Diagnostics will pair SOPHiA DDM™ for Hereditary Cancers Solution with their laboratory analysis technologies."

"SOPHiA GENETICS...is partnering with Agilent to offer a comprehensive solution for cancer analysis...Through the partnership, the SOPHiA DDM Platform will be integrated with Agilent’s new Research Use Only SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay Kit. This will enable clinical researchers to accurately identify multiple biomarkers, lowering the risk of missing important information in cancer samples. The partnership brings together these two companies’ strengths in analytics and next generation sequencing (NGS) assay development to facilitate novel approaches to cancer research."

"SOPHiA GENETICS...announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS’ platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM™ platform to gain deeper insights into hematologic malignancies."

"SOPHiA GENETICS...announced a new partnership with QIAGEN...that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS). The partnership will allow customers to order QIAseq panels that can be processed through SOPHiA DDM™, a cloud-based platform that analyzes data from various sources to enable entirely new research perspectives. The partnership will initially support somatic variant detection (an alteration in DNA that occurs after birth) using QIAseq Targeted DNA Pro panels for homologous recombination repair (HRR), a special type of biomarker test to find tumors that have certain mutations that may make them sensitive to PARP inhibitors in oncology."

"SOPHiA GENETICS...announced that Synergy Oncology, part of Synergy Laboratories...will use SOPHiA DDM™ to develop a new cancer profiling solution. The combination of technology from Synergy Oncology and SOPHiA GENETICS will expand Synergy’s oncology portfolio while helping to further the U.S. oncology market...Synergy Oncology...will pair SOPHiA DDM™ for Hereditary Cancers Solution with their state-of-the-art laboratory technologies to launch Totality, a comprehensive end-to-end solution for tumor profiling that will benefit cancer research, clinical studies, and patient care."

"Sophia Genetics said...that it has entered into a collaboration with New York's Memorial Sloan Kettering Cancer Center to combine predictive algorithms in a quest to offer new testing and analytical capabilities to cancer researchers and clinicians worldwide...Sophia will help the cancer center commercialize its MSK-ACCESS clinical liquid biopsy assay. Sophia said that the test will be the first circulating tumor DNA panel to be integrated with the company's flagship DDM analytics platform."